WJPR Citation New

  All Since 2011
 Citation  2903  2393
 h-index  27  24
 i10-index  68  60

Login

Best Paper Awards

World Journal of Pharmaceutical Research (WJPR) will give best paper award in every issue in the form of money along with certificate to promote research activity of scholar.
Best Paper Award :
Dr. Dhrubo Jyoti Sen
Download Article: Click Here

Search

Track Your Article

Abstract

EFFICACY OF JAK-STAT INHIBITORS IN RHEUMATOID ARTHRITIS

Arathy R.*, Shiraz S., Dona Benny and Sini S. G.

Abstract

Rheumatoid arthritis (RA) is a leading cause of musculoskeletal disease worldwide. Disease Modifying Anti-Rheumatic Drugs have been used to treat RA. The treatment has advanced due to the introduction of biological disease modifying anti-rheumatic drugs. Janus kinase (JAK) inhibitors or JAKinhibs are orally available biological disease modifying anti- rheumatic drugs. Tofacitinib was the first FDA-approved JAK inhibitor. Another drug baricitinib also demonstrated efficacy in treating RA. Many other JAKinhibs are currently in clinical trials. These drugs act by inhibiting the JAKSTAT pathway which plays an important role in the pathophysiology of RA. JAK inhibitors differ by their selectivity towards JAKs. In this review, we summarize the efficacy and safety of JAK inhibitors in rheumatoid arthritis.

Keywords: Rheumatoid arthritis, DMARDs, JAK-STAT pathway, Janus kinase inhibitors, Tofacitinib, Baricitinib.


[Full Text Article]

Call for Paper

World Journal of Pharmaceutical Research (WJPR)
Read More

Email & SMS Alert

World Journal of Pharmaceutical Research (WJPR)
Read More

Article Statistics

World Journal of Pharmaceutical Research (WJPR)
Read More

Online Submission

World Journal of Pharmaceutical Research (WJPR)
Read More